Analysis and Commentary 1/12/17 Analysis and Commentary 1/12/17 Advocacy and the "Iron Triangle" of Deficit Reduction Read More Analysis and Commentary 1/6/17 Analysis and Commentary 1/6/17 The Speedy Appointment of a New Commissioner? Read More Analysis and Commentary 12/16/16 Analysis and Commentary 12/16/16 Time for a Deep Breath Before the New Year Begins Read More Analysis and Commentary 12/8/16 Analysis and Commentary 12/8/16 Setting the Advocacy Stage for FY 18 and After Read More Analysis and Commentary 12/5/16 Analysis and Commentary 12/5/16 21st Century Cures Passes House -- with Pros and Cons Read More Analysis and Commentary 11/21/16 Analysis and Commentary 11/21/16 Significant Change Is Always Hard Read More Analysis and Commentary 11/11/16 Analysis and Commentary 11/11/16 Ensuring and Advocating for an FDA that Works Read More Analysis and Commentary 11/7/16 Analysis and Commentary 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More Analysis and Commentary 10/28/16 Analysis and Commentary 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More Analysis and Commentary 10/21/16 Analysis and Commentary 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More Analysis and Commentary 10/14/16 Analysis and Commentary 10/14/16 And Now Much Depends on Election Day Outcomes Read More Analysis and Commentary 9/23/16 Analysis and Commentary 9/23/16 FDA Purchasing Power is on the Line Read More Analysis and Commentary 9/16/16 Analysis and Commentary 9/16/16 What to Expect When You are Expecting a Lame Duck Read More Analysis and Commentary 9/9/16 Analysis and Commentary 9/9/16 Omnibus, Minibus, or Any Type of Bus at All? Read More Analysis and Commentary 8/28/16 Analysis and Commentary 8/28/16 The Cost -- and the Importance -- of Public Attention Read More Analysis and Commentary 8/20/16 Analysis and Commentary 8/20/16 Exceptionalism in Predictably Challenging Times Read More Analysis and Commentary 8/15/16 Analysis and Commentary 8/15/16 Management of Accountability to Varied Audiences Read More Analysis and Commentary 7/29/16 Analysis and Commentary 7/29/16 FDA Must Do More ... But How Much More for Less? Read More Analysis and Commentary 7/22/16 Analysis and Commentary 7/22/16 No Taking Sides Here at the Alliance! Read More Analysis and Commentary 7/15/16 Analysis and Commentary 7/15/16 Coming Soon: A Future Year of Massive Change Read More Newer Posts Older Posts
Analysis and Commentary 1/12/17 Analysis and Commentary 1/12/17 Advocacy and the "Iron Triangle" of Deficit Reduction Read More
Analysis and Commentary 1/6/17 Analysis and Commentary 1/6/17 The Speedy Appointment of a New Commissioner? Read More
Analysis and Commentary 12/16/16 Analysis and Commentary 12/16/16 Time for a Deep Breath Before the New Year Begins Read More
Analysis and Commentary 12/8/16 Analysis and Commentary 12/8/16 Setting the Advocacy Stage for FY 18 and After Read More
Analysis and Commentary 12/5/16 Analysis and Commentary 12/5/16 21st Century Cures Passes House -- with Pros and Cons Read More
Analysis and Commentary 11/21/16 Analysis and Commentary 11/21/16 Significant Change Is Always Hard Read More
Analysis and Commentary 11/11/16 Analysis and Commentary 11/11/16 Ensuring and Advocating for an FDA that Works Read More
Analysis and Commentary 11/7/16 Analysis and Commentary 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More
Analysis and Commentary 10/28/16 Analysis and Commentary 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More
Analysis and Commentary 10/21/16 Analysis and Commentary 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More
Analysis and Commentary 10/14/16 Analysis and Commentary 10/14/16 And Now Much Depends on Election Day Outcomes Read More
Analysis and Commentary 9/23/16 Analysis and Commentary 9/23/16 FDA Purchasing Power is on the Line Read More
Analysis and Commentary 9/16/16 Analysis and Commentary 9/16/16 What to Expect When You are Expecting a Lame Duck Read More
Analysis and Commentary 9/9/16 Analysis and Commentary 9/9/16 Omnibus, Minibus, or Any Type of Bus at All? Read More
Analysis and Commentary 8/28/16 Analysis and Commentary 8/28/16 The Cost -- and the Importance -- of Public Attention Read More
Analysis and Commentary 8/20/16 Analysis and Commentary 8/20/16 Exceptionalism in Predictably Challenging Times Read More
Analysis and Commentary 8/15/16 Analysis and Commentary 8/15/16 Management of Accountability to Varied Audiences Read More
Analysis and Commentary 7/29/16 Analysis and Commentary 7/29/16 FDA Must Do More ... But How Much More for Less? Read More
Analysis and Commentary 7/22/16 Analysis and Commentary 7/22/16 No Taking Sides Here at the Alliance! Read More
Analysis and Commentary 7/15/16 Analysis and Commentary 7/15/16 Coming Soon: A Future Year of Massive Change Read More
